Last updated: May 26, 2026
NAROPIN is the brand name for ropivacaine hydrochloride, an amide local anesthetic. The supplier map depends on the specific dosage form and strength (injectable), the U.S. marketing authorization holder, and the current manufacturing and packaging sites listed on the FDA label and in the Orange Book for the referenced product. Without the specific Naropin NDC(s), strength, and dosage form (single-dose vial vs. infusion-related presentations), a complete, accurate supplier roster cannot be produced.
Who supplies Naropin (ropivacaine) for U.S. distribution?
Direct answer: Naropin supply in the U.S. runs through the FDA-labeled manufacturer(s) and the commercial marketing authorization holder for the referenced NDA product for ropivacaine HCl injectable. The “supplier” for procurement purposes is the labeled manufacturer and, where applicable, the secondary packager/filler identified on the U.S. label for each NDC.
What determines “supplier” in NAROPIN procurement?
Common procurement-relevant supplier roles for injectable products:
- Primary manufacturer (drug substance and drug product manufacture, if combined)
- Fill-finish site (aseptic fill, stoppering, labeling for vials)
- Secondary packaging (cartoning, labeling, kit assembly if applicable)
- Distributor/labeler (NDA holder entity on the label; often the same as marketing authorization holder)
Which companies manufacture ropivacaine hydrochloride injectable (Naropin) by NDC strength?
Direct answer: Manufacturing attribution must be tied to the exact NDC and presentation because different strengths can be produced/packed at different sites, including transfers between fill-finish locations across years.
NDC-level mapping needed for a defensible supplier list
A proper supplier table should include:
- NDC
- Strength (mg/mL)
- Container (vial volume)
- Labeler/marketing entity
- Labeled manufacturer and site address
- Labeled packager/filler and site address
- Controlled substance handling notes (if any) and storage conditions relevant to distribution
What is the Orange Book status of Naropin ropivacaine and does it affect supply?
Direct answer: Orange Book listings can affect supply only indirectly through IP and exclusivity-driven licensing and generic entry timing. Supplier selection itself is determined by manufacturing authorizations, validated processes, and distribution approvals, not by Orange Book status.
How Orange Book affects supply-chain timing
- If Orange Book-protected formulation or method patents block generic approval or launch timing, generic supplier capacity is delayed.
- If exclusivity or patent barriers lift, additional suppliers may enter as ANDA holders begin fill-finish manufacturing runs.
Do Naropin generics change the supplier landscape?
Direct answer: Yes, once generics are approved and launched under ANDAs with validated manufacturing and packaging sites, the number of qualified suppliers typically expands. The magnitude depends on:
- number of approved ANDAs per strength/presentation
- whether generics use the same supply chain sites or different fill-finish facilities
- market adoption and channel contracting
Generic entry risks that influence “who supplies”
- Process validation lead times for sterile injectable manufacturing
- Site approvals and inspections
- Labeling and packaging line readiness
- API sourcing continuity for ropivacaine HCl
What patent and regulatory barriers influence new suppliers for ropivacaine injectable?
Direct answer: Regulatory barriers include sterility assurance, aseptic process validation, and stability across the shelf-life. Patent barriers include Orange Book-listed patents and listed exclusivity where applicable.
Regulatory friction points for injectables
- Aseptic fill-finish process validation
- Container closure integrity and particulate matter controls
- Stability data package acceptance for each vial configuration
IP friction points
- Formulation and salt-related claims (if applicable to the referenced product)
- Method-of-use or dosing regimen claims
- Device or administration route claims (if the formulation interacts with delivery method)
How to build a reliable Naropin supplier roster for procurement
Direct answer: A defensible supplier roster is built from:
- FDA label manufacturing and packaging statements for each NDC
- Orange Book referenced product linkage to identify legal marketing entity and product scope
- ANDA/AB-rated product labels for generic competitors, mapped by NDC and fill-finish site
Supplier table structure (required for operational use)
| Product (presentation) |
NDC |
Strength |
Labeler/Marketing entity |
Labeled manufacturer site |
Labeled packager/filler site |
Source basis (Label/Orange Book) |
| Naropin injectable |
(insert NDC) |
(insert mg/mL) |
(insert labeler) |
(insert site) |
(insert site) |
FDA label + Orange Book referenced product |
Competitive landscape: branded Naropin vs. generic ropivacaine HCl injectable suppliers
Direct answer: The competitive landscape depends on which strengths and container sizes are covered by approved ANDAs. Without the specific NDCs, the supplier count and names cannot be stated accurately.
What to compare across suppliers
- Per-NDC approval coverage: do generics cover the exact vial size?
- Pack-out format: vial configuration and presentation
- Manufacturing site: primary fill-finish location
- Commercial availability: wholesaler listings by NDC (lead times)
Key takeaways
- “Supplier for NAROPIN” is not a single company across all presentations. It must be mapped by NDC/strength/container to the FDA-labeled manufacturer and, when listed, the packager/filler sites.
- Orange Book status affects competitive entry timing but does not directly determine who can manufacture the referenced product.
- A procurement-grade supplier roster requires label-derived site attribution per NDC, plus Orange Book and ANDA product mapping for generics.
FAQs
- Which NAROPIN NDCs have different manufacturing sites by strength?
- How do FDA label “manufactured for” statements differ from “packaged by” for Naropin procurement?
- Do ropivacaine HCl injectable generics use the same fill-finish facilities as branded Naropin?
- What regulatory requirements most delay new supplier qualification for sterile injectable local anesthetics?
- How can an NDC-level supplier change affect drug availability and distributor contracting terms?
References
- FDA Orange Book. NAROPIN (ropivacaine hydrochloride) drug patent information. U.S. Food and Drug Administration.
- U.S. FDA. NAROPIN (ropivacaine hydrochloride) prescribing information and labeling.
